Recent Updates
Recently added Catalysts

Crizanlizumab

Phase 3

Sickle Cell Disease | Monoclonal antibody | Hematology |Novartis AG|Last Updated: May 27, 2026

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindPLACEBO_CONTROLLEDBiomarker
Total Trials1
Total Enrollment315
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT06439082A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)PHASE3 RECRUITING 315Oct 24, 2024Apr 19, 2030May 27, 202632 United States, Brazil +3
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Annualized rate of VOCs that are healthcare professional (HCP)-managed (including VOCs leading to management at a health care facility or those managed via remote consultation) in each treatment arm
1 year

Vaso oclusive crisis (VOC) is defined as a pain crisis (acute onset of pain for which there is no other medically determined explanation other than vaso-occlusion) lasting for at least 4 hours which is treated as per local guidelines with standard of care therapy used to treat VOC. Acute chest syndrome (ACS), priapism and hepatic or splenic sequestration will be considered VOC in this study. VOCs included are those HCP-managed in a healthcare facility and HCP-managed via remote consultation. Annualized rate of VOC events = (Number of VOC events \* 365)/(number of days in the observation period). Observation period = time from date of randomization to minimum of (last dose date until treatment discontinuation + 27 days, date of initiation or discontinuation of HU/HC or L-Glutamine (or other therapies such as Voxelotor and erythropoietin therapies to treat SCD and/or to prevent/reduce VOCs), date of randomization + 365 days).

Secondary Endpoints
The annualized rate of all VOCs including VOCs that are HCP-managed (either at a health care facility or via remote consultation) as well as those that are self-managed without recommendations from HCP during the event in each treatment arm
1 year
Annualized rate of VOC by subtype of management in each treatment arm over the planned 52-week period.
1 year
The time to first VOC that is HCP-managed (including VOCs leading to management at a health care facility or those managed via remote consultation) between treatment arms.
1 year
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingQUADRUPLE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
Crizanlizumab (SEG101) at 5.0 mg/kgEXPERIMENTALParticipants receive Crizanlizumab (SEG101) at 5.0 mg/kg and standard of care.
PlaceboPLACEBO_COMPARATORParticipants receive the placebo drug and standard of care.
Interventions
NameTypeDescription
CrizanlizumabBIOLOGICALCrizanlizumab is supplied in single use 10 mL glass vials at a concentration of 10 mg/mL. One vial contains 100 mg of crizanlizumab. This is a concentrate for solution for IV infusion.
PlaceboDRUGPlacebo is supplied in single use 10 mL glass vials at a concentration of 0 mg/mL. This is a concentrate for solution for IV infusion.
Unlock Study Design Details
Eligibility Criteria
Age Range12 Years — 100 Years
SexALL
Healthy VolunteersNo
Study Sites32

Key Inclusion Criteria: 1. Participants must be aged 12 years and older on the day of signing informed consent. Adolescents include participants aged 12 to \<18 years old and adults include participants aged 18 years and older. 2. Confirmed diagnosis of SCD by Hb electrophoresis or high-performance...

Countries:United StatesBrazilColombiaKenyaUganda
Unlock Eligibility Criteria
Recent Changes (Last 90 Days)
LOWMay 28, 2026NCT06439082lastUpdatePostDate: changed
LOWMay 28, 2026NCT06439082lastUpdatePostDate: changed
LOWMay 26, 2026NCT06439082primaryCompletionDate: changed
LOWMay 24, 2026NCT06439082studyFirstPostDate: changed